Nephros (NASDAQ:NEPH – Get Free Report) and ImmuCell (NASDAQ:ICCC – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Valuation and Earnings
This table compares Nephros and ImmuCell”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nephros | $14.16 million | 2.83 | $70,000.00 | $0.13 | 29.00 |
| ImmuCell | $26.49 million | 2.21 | -$2.16 million | $0.26 | 24.92 |
Analyst Ratings
This is a summary of current ratings and recommmendations for Nephros and ImmuCell, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nephros | 0 | 1 | 1 | 0 | 2.50 |
| ImmuCell | 1 | 0 | 0 | 0 | 1.00 |
Nephros presently has a consensus price target of $6.00, indicating a potential upside of 59.15%. Given Nephros’ stronger consensus rating and higher possible upside, research analysts plainly believe Nephros is more favorable than ImmuCell.
Profitability
This table compares Nephros and ImmuCell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nephros | 8.26% | 15.81% | 12.22% |
| ImmuCell | 8.37% | 8.00% | 5.07% |
Volatility and Risk
Nephros has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Insider & Institutional Ownership
41.1% of Nephros shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 5.6% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Nephros beats ImmuCell on 11 of the 14 factors compared between the two stocks.
About Nephros
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.
